

1 Effects of graded dietary docosahexaenoic acid in combination with other long-chain polyunsaturated  
2 fatty acids in post-smolt Atlantic salmon (*Salmo salar*) : Performance characterisation, health and  
3 behavioural effects

4

5

6 Brett D. Glencross<sup>1</sup>, Douglas R. Tocher<sup>2</sup>, Chessor Matthew<sup>3</sup>, J. Gordon Bell<sup>2</sup>

7

8

9 1. CSIRO Food Futures Flagship - CSIRO Marine and Atmospheric Research, GPO Box 2583,  
10 Brisbane, QLD 4001, Australia

11 2. Institute of Aquaculture, School of Natural Sciences, University of Stirling, Stirling FK9 4LA,  
12 Scotland

13 3. Marine Environment Research Laboratory, Machrihanish PA28 6PZ, Scotland

14

15 (p) 61-7-3833-5926

16 (e) Brett.Glencross@csiro.au

17

18

19 Keywords : Atlantic salmon, Essential fatty acid, DHA, ARA, EPA, Fish health, Behaviour

20

21

22 **Abstract**

23

24 A dietary dose-response study with varying docosahexaenoic acid (DHA; 22:6n-3) inclusion  
25 levels (1 g/kg, 5 g/kg, 10 g/kg, 15 g/kg and 20 g/kg) was conducted with post-smolt ( $111 \pm 2.6$ ;  
26 mean  $\pm$  S.D.) Atlantic salmon (*Salmo salar*) over a nine week feeding period. Further diets included  
27 DHA at 10 g/kg in combination with either eicosapentaenoic acid (EPA; 20:5n-3) or arachidonic acid  
28 (ARA; 20:4n-6), both included at 10 g/kg, and a diet where both EPA and DHA were included at 5  
29 g/kg (total of 10 g/kg of long-chain polyunsaturated fatty acids, LC-PUFA). Fish were fed using a  
30 pair-feeding feeding regime to eliminate feed and energy intake variability. Fish were weighed every  
31 three weeks, and carcass, blood and tissue samples collected after nine weeks. Behavioural parameters  
32 were assessed weekly. A minor improvement in growth was seen with increasing inclusion of DHA.  
33 However, the addition of EPA provided a further improved growth response while addition of ARA  
34 had no effect on growth. An improvement in feeding behaviour was seen with increasing DHA up to  
35 10 g/kg, and addition of EPA or ARA had only minor effects on behavioural responses. Temporal  
36 differences were observed in the survival of fish, with the addition of ARA resulting in a progressive  
37 decline in survival relative to fish fed the other diets. In contrast, the survival of fish on the low DHA  
38 diet (1 g/kg) was initially high but declined from 6 weeks onwards. As expected, the fatty acid  
39 composition of whole body lipid largely reflected the diets. Deposition efficiency of dietary fatty  
40 acids was generally unresponsive to the different dietary treatments with the notable exception of  
41 DHA. At very low inclusion levels DHA deposition efficiency was substantially higher (~300 %) than  
42 that for all other inclusion levels (31 % to 58 %). The inclusion of EPA in the diet also had a positive  
43 effect on the deposition efficiency of DHA but EPA deposition efficiency was variable. Deposition  
44 efficiency of ARA was unaffected by DHA inclusion, but addition of either EPA or ARA resulted in a  
45 substantial reduction in the deposition efficiency of ARA. In the present study, the results suggested  
46 that inclusion of DHA of at least 10 g/kg diet is optimal. Addition of either EPA or ARA had a  
47 nominal influence on the effects of DHA, although inclusion of EPA appeared to improve  
48 performance. When the total n-3 LC-PUFA content of the diet was the same but consisted of either  
49 DHA alone or as a combination of EPA plus DHA the performance effects were similar, but  
50 behavioural effects in this study were more related to DHA content than total n-3 LC-PUFA content.

51

## 52 1. Introduction

53 The relatively static global supply of fish oil resources has increased the level of alternative  
54 (vegetable and terrestrial animal) oil resources being used in fish feeds (Tacon and Metian, 2008).  
55 Many alternatives have been evaluated in a wide range of fish species over the last few years and, in  
56 most cases, it has been demonstrated that high-level replacement of fish oils is possible (Sales and  
57 Glencross, 2010). However, most of the alternatives now commonly being used (e.g. rapeseed,  
58 soybean and poultry oils) are notable in their lack of long-chain polyunsaturated fatty acids (LC-  
59 PUFA) and, with increasing use of these alternative lipid sources and the concomitant use of  
60 alternative protein resources rather than fish meals, some diets are beginning to encroach on  
61 documented dietary levels of essential fatty acids (EFA) for some species (Glencross, 2009).

62 Most aquatic species have some form of requirement for EFA as dietary nutrients (reviewed  
63 by Glencross, 2009). However, which specific fatty acid (n-3 or n-6, long-chain or C18) satisfies EFA  
64 requirements, their concentration in the diet, and how the value of an EFA is influenced by the  
65 presence of other dietary fatty acids appears to vary markedly among species (Glencross and Smith,  
66 2001). It is generally considered that marine species have a higher, or more defined requirement, for  
67 the LC-PUFA docosahexaenoic acid (DHA; 22:6n-3) or eicosapentaenoic acid (EPA; 20:5n-3), while  
68 diadromous species have a lower requirement and some freshwater species appear to have no  
69 requirement at all for LC-PUFA (Bell et al., 1986; Castell et al., 1994; Tocher, 2003; Glencross,  
70 2009).

71 Unlike most marine species salmonids possess the ability to elongate and desaturate  $\alpha$ -  
72 linolenic acid (LNA; 18:3n-3) to produce EPA and DHA (Castell et al., 1972a; b; Thomassen et al.,  
73 2012). However, in the absence of dietary LNA or other n-3 LC-PUFA rainbow trout have been  
74 shown to produce elevated levels of 20:3n-9 (Castell et al. 1972c). It has been suggested that the ratio  
75 of 20:3n-9 to DHA in liver phospholipids of rainbow trout serves as an indicator of EFA deficiency  
76 (Castell et al. 1972b). In terms of the dietary requirement of salmonids for n-3 LC-PUFA, this has  
77 been reported to range from 10 g/kg to 25 g/kg of the diet depending on species and experimental  
78 conditions (reviewed by Glencross, 2009). The early studies of Castell et al. (1972a; 1972b) with  
79 rainbow trout (*Oncorhynchus mykiss*) focussed on the requirement for linoleic acid (LOA; 18:2n-6) or  
80 LNA and found that growth was significantly better with LNA over LOA or an EFA deficient diet.  
81 However, the value of LNA as an EFA for trout exists only because it has significant ability to  
82 desaturate and elongate LNA to the biologically active LC-PUFA, EPA and DHA (Castell et al.,  
83 1972a,b; Thomassen et al., 2012). These studies also demonstrated that there was no requirement for  
84 n-6 PUFA by rainbow trout (Castell et al., 1972a,b), though this notion was later challenged by the  
85 assertion that trout may require small amounts of n-6, specifically arachidonic acid (ARA; 20:4n-6),  
86 for prostaglandin and leukotriene synthesis (Henderson et al., 1985; Villalta et al., 2008).

87 Although the early work of Castell et al. (1972a, b) defined a requirement for n-3 PUFA, it  
88 was a series of studies on Atlantic salmon fry undertaken by Ruyter et al. (2000a) that went on to

89 examine the quantitative and qualitative EFA requirements for LOA, LNA and, EPA and DHA in  
90 combination. It was shown that inclusion of LNA, and EPA and DHA in combination both provided  
91 significant nutritional benefits to the fish. Of all treatments examined, the 50:50 combination of EPA  
92 and DHA at 10 g/kg provided the greatest benefit. Interestingly, Ruyter et al. (2000a) also showed  
93 poorer growth of fish fed 20 g/kg of either LNA or EPA and DHA. This was consistent with the  
94 earlier reports of Yu and Sinnhuber (1979), who also reported that excess levels of LC-PUFA had a  
95 negative impact on growth. Therefore, there is accumulating evidence that providing an excess  
96 amount of n-3 LC-PUFA in the diet can have adverse effects on growth and food utilization.  
97 However, in the work by Ruyter et al. (2000a) the roles of the LC-PUFA of DHA and EPA were only  
98 examined in combination. Recent studies with Asian seabass (*Lates calcarifer*; aka barramundi) have  
99 reported discrete effects of DHA alone or in the presence of EPA, and verified the synergistic  
100 importance of both (Glencross and Rutherford, 2011). Additionally, the influence of the n-6 LC-  
101 PUFA, ARA, has also been assessed and showed some contrasting effects to that observed with the  
102 inclusion of EPA, reflective of the competing roles that these fatty acids have in the pathways for  
103 eicosanoid synthesis (Terano et al., 1986; Garg et al., 1990; Garg and Li, 1994; Bell et al., 1995). A  
104 more recent study by Codabaccus et al., (2012) also examined the response of post-smolt Atlantic  
105 salmon to DHA. However, this study showed no growth effects to the manipulation of the dietary  
106 fatty acid profile, but we believe this result was constrained by the design of the experiment.

107         Based on the earlier work by Ruyter et al (2000a), it was hypothesized that post-smolt  
108 Atlantic salmon will have a quantitative dietary DHA requirement of around 10 g/kg. Based on  
109 studies with Asian sea bass it was also hypothesized that the response to this dietary level of DHA  
110 may be affected by the presence of other LC-PUFA in the diet (Glencross and Rutherford, 2011). The  
111 present study therefore examined the inclusion of incremental levels of dietary DHA on performance  
112 attributes of post-smolt Atlantic salmon. The study was not primarily designed to determine optimal  
113 feed specifications but rather aimed to specifically investigate the requirement for dietary DHA and  
114 its interaction with other dietary LC-PUFA. Accordingly, a paired-feeding strategy was adopted to  
115 eliminate the confounding effects of variation of intake of other dietary nutrients and energy. The  
116 study included a further three treatments to examine the effect of dietary EPA and ARA on the  
117 response of this species to dietary DHA. Whilst the primary parameter evaluated in this study was  
118 growth performance it was hypothesized that many of the dietary effects would be sub-clinical and  
119 therefore a range of biochemical, compositional, health and behavioural studies were also included to  
120 elucidate the specific mechanisms of DHA and possible interactions with other key LC-PUFA in the  
121 diet.

122

## 123 2. Materials and Methods

124

### 125 2.1 Diet manufacture and management

126 A single basal diet was formulated to provide protein and lipid at 460 g/kg and 200 g/kg diet  
127 at a gross energy level of 22.0 MJ kg<sup>-1</sup> (estimated digestible protein and energy of 440 g/kg and 19.5  
128 MJ kg<sup>-1</sup>, respectively). Of the dietary lipid, 185 g/kg was vacuum-infused post-extrusion and it was at  
129 this point that the different treatments were made by infusing different oil blends. The fishmeal was  
130 defatted by hexane extraction followed by drying at 60 °C for 24 h to remove all residual solvent. The  
131 nutrient compositions of the main dietary ingredients are presented in Table 1. To produce the basal  
132 diet pellets, the dry ingredients were blended in 30 kg batches to make a pellet mash using a 60 L  
133 upright Hobart mixer (HL600, Hobart, Pinkenba, QLD, Australia). The mash was pelletized using a  
134 laboratory-scale twin-screw extruder (MPF24:25, Baker Perkins, Peterborough, United Kingdom).  
135 Extruder configurations were as defined in Glencross et al. (2012). A single 130 kg batch of basal diet  
136 was extruded using the same operational parameters for consistency.

137 A series of five DHA inclusion levels (D1, D5, D10, D15 and D20) were created by blending  
138 oils including an algal-derived (*Cryptocodinium* sp.) DHA oil source (DHASCO) and a blend of  
139 butterfat and olive oil to provide the lipid base (Table 2). Three additional treatments were included to  
140 examine the accessory inclusion of ARA or EPA. The ARA was added as the fungal-derived  
141 concentrate (ARASCO) to provide inclusion levels of 10 g/kg each of ARA and DHA (D10A). As  
142 there was no equivalent EPA concentrate equivalent to DHASCO or ARASCO, anchovy oil  
143 containing both EPA and DHA in equal amounts was used to formulate the DHA/EPA diets, with  
144 addition to provide inclusion levels of either 10 g/kg (D10E) or 5 g/kg (D5E) each of EPA and DHA.  
145 Full diet compositions are given in Table 3. The oil blends were prepared prior to vacuum coating and  
146 were thoroughly mixed before being applied. The butterfat was melted at 60 °C for 2 h and any  
147 remaining solids decanted to waste prior to addition to the oil blends. Dry basal pellets were placed in  
148 a mixer (Hobart, Sydney, Australia) and the prescribed allocation of oil blend applied whilst mixing,  
149 after which the bowl was sealed with a Perspex lid and a vacuum applied. Once all visible signs of air  
150 escaping from the pellets had ceased, the vacuum chamber was re-equilibrated to atmospheric  
151 pressure and the oil infused into the pellet.

152

### 153 2.2 Fish management

154 Pre-smolt Atlantic salmon were sourced from Howietoun fish hatchery (Bannockburn,  
155 Scotland) and transferred to the Marine Environmental Research Laboratory (MERL, Machrihanish,  
156 Argyll, Scotland). At MERL the fish were allocated to two 10,000 L seawater tanks and on-grown to  
157 110.9 ± 2.61 g (mean ± S.D) prior to the experiment. All fish were anaesthetised using benzocaine  
158 prior to handling. The fish were weighed on an electronic top-loading balance to 0.5 g accuracy and  
159 20 fish allocated to each of 24 x 500 L tanks. Fish were re-weighed at day 21, day 42 and finally on

160 day 62 of the experiment. The experiment was conducted in a flow-through, ambient water  
161 temperature, 500L x 24-tank array. Water temperature was  $14.0 \pm 0.82$  °C (mean  $\pm$  S.D.) and  
162 dissolved oxygen was at  $7.8 \pm 0.60$  mg L<sup>-1</sup> (mean  $\pm$  S.D.) for the duration of the 62-day experiment.  
163 Three replicates (tanks of 20 fish) were used for each treatment.

164 During the experiment, feeds were provided on a restricted pair-wise feeding regime with  
165 uneaten feed collected to accurately determine feed intake per tank (Helland et al., 1996). A  
166 correction factor was applied to recovered uneaten pellets to account for soluble losses incurred  
167 between feeding and collection to improve accuracy of feed intake assessment. The initial restrictive  
168 rations were estimated based on an 80 % demand as estimated for a 19.5 MJ kg<sup>-1</sup> diet at 12 °C using a  
169 bioenergetic model for salmon (B. Glencross, unpublished). Subject to all rations being consumed by  
170 each tank, the ration allocations were incrementally increased uniformly by 0.25 g fish<sup>-1</sup> each week  
171 from a base allocation of 1.0 g fish<sup>-1</sup>. Total feed fed per fish is presented in Table 4.

172

### 173 2.3 *Sample preparation and analysis*

174 At the beginning of the study, six fish representative of the initial population were euthanized,  
175 dried of residual surface moisture and frozen for subsequent compositional analysis in three lots of  
176 two fish. At the end of the experiment (day 62), after final weighing, five fish from each tank were  
177 similarly sampled and frozen for compositional analysis. The fish from each tank were minced  
178 together after defrosting and a sample taken for dry matter analysis and another frozen prior to being  
179 freeze-dried. The freeze-dried whole fish samples were milled to a fine powder before being analysed  
180 for dry matter, nitrogen (protein), ash, total lipid content, and fatty acid compositions. Blood samples  
181 (~10 mL total) were collected from the caudal vein of an additional two fish per tank and pooled  
182 within a single Falcon™ tube, containing 100 IU of lithium heparin. About half the blood was  
183 transferred to three Eppendorf™ tubes before being centrifuged at 1000 x g for ~2 min to sediment  
184 the erythrocytes and the plasma transferred to a Cryotube™ prior to being frozen in liquid nitrogen.  
185 The remaining blood was kept on ice and haematological analysis performed within 24 h of collection  
186 (Scottish Agricultural College Veterinary Services, Penicuik, Scotland). Clinical biochemical analysis  
187 was performed on frozen plasma using an automated chemistry analyser (AU400, Olympus Optical  
188 Co. Ltd) using standard assay kits developed for the auto-analyser (Scottish Agricultural College  
189 Veterinary Services, Penicuik, Scotland).

190 Moisture and ash contents of diets and fish were determined according to standard procedures  
191 (AOAC, 2000). Dry matter was assessed gravimetrically following oven drying at 105 °C for 24 h,  
192 and gross ash content was determined gravimetrically after combustion in a muffle furnace at 550 °C  
193 for 12 h. Energy contents of the diets were measured by bomb calorimetry using a Parr 6200  
194 calorimeter according to standard procedures. Crude protein levels were calculated from the nitrogen  
195 content ( $N \times 6.25$ ) using automated Kjeldahl analysis (Tecator Kjeltac Auto 1030 analyser, Foss,  
196 Warrington, UK). Lipid contents were determined gravimetrically after extraction according to Folch

197 et al. (1957). Fatty acid compositions were determined by gas chromatography of methyl esters  
198 essentially according to Christie (2003). Individual methyl esters were identified by comparison with  
199 known standards and by reference to published data (Ackman, 1980; Tocher and Harvie, 1988), and  
200 quantified using Chromcard for Windows (version 1.19).

201

#### 202 2.4 *Behaviour analysis*

203 Two methods were used to assess the behavioural response of tanks of fish. Method one  
204 scored feeding activity after one round of feed had already been fed as described previously for Asian  
205 sea bass (Glencross and Rutherford, 2011). A score of 2 was given when fish actively came to the  
206 surface and pursued feed, a score of 1 for fish feeding actively but not breaking the surface to pursue  
207 feed, and a score of 0 for fish that were slow to feed and appeared lethargic in their behaviour. This  
208 semi-subjective assessment was carried out by the same person once a week for each of the nine  
209 weeks of the study. Scores were averaged across time to give a repeated-measures response to each  
210 tank, and each tank was used as a replicate within each treatment. This is similar to that which was  
211 reported in Glencross and Rutherford (2011). However, the behaviour of the salmon in this  
212 experiment was substantially different to that of the Asian sea bass in the work by Glencross and  
213 Rutherford (2011), with the fish always remaining timid and never being able to relate the presence of  
214 a person to feed allocation. As such the behaviour scoring was more difficult in the case of salmon.

215 A second, more objective, indicator of feeding behaviour, the number of pellets remaining in  
216 the feed container after two rounds of feeding relative to the total number of pellets allocated, was  
217 determined. The fish were fed to a point of notable decline in active feeding before cessation of  
218 feeding. This assessment was also carried out by the same person once a week for each of the nine  
219 weeks of the study except weeks 5 and 7. Scores were again averaged across time to give a repeated-  
220 measures response to each tank and each tank used as a replicate within each treatment.

221

#### 222 2.5 *Physical health assessment*

223 At the end of the study, a series of physical condition features were noted and recorded for all  
224 fish within each tank. The incidence of conditions such as pectoral fin erosion, caudal fin reddening or  
225 erosion, skin lesions/scale loss, pin-heading and eye malformations were assessed to give a percentage  
226 value for each parameter for each tank. A systemic outbreak of amoebic gill disease (AGD) was also  
227 present in the facility during the experimental period at low levels and was controlled by giving all  
228 fish a 2 h freshwater bath treatment once a month. Accordingly, at week 9 an AGD gill score was  
229 given for each fish based on that reported by Taylor et al. (2009). The scoring for health parameters  
230 was carried out by the same person for all fish and at each time point.

231

232 2.6 *Statistical analyses*

233 All figures are mean  $\pm$  SEM unless otherwise specified. Effects between D10, D20, D10A,  
234 D10E and D5E were examined by ANOVA using the software package Statistica (Statsoft®, Tulsa,  
235 OA, USA). Levels of significance were determined using an LSD planned comparisons test, with  
236 critical limits being set at  $P < 0.05$ . Effects of DHA inclusion level (D1, D5, D10, D15 and D20) were  
237 analysed by regression analysis.

238 Relative deposition efficiency (%) of specific fatty acids (DHA, EPA, ARA, LNA and LOA)  
239 was calculated using the mean intake per fish in each tank and the mean gain in mass of specific fatty  
240 acids by fish in that tank, over the duration of the study, to give tank-specific values that were then  
241 used to derive a treatment mean. The formula used was based on that reported by Glencross et al.,  
242 (2003), where  $FAf$  is the absolute amount of a specific fatty acid in the fish at the end of the study and  
243  $FAi$  is the absolute amount of that specific fatty acid in the fish at the beginning of the study.  $FAc$  is  
244 the amount of that specific fatty acid that the fish consumed over the study period, such that:

245

$$Fatty\ Acid\ Deposition\ Efficiency\ (\%) = \left( \frac{FAf - FAi}{FAc} \right) \times 100$$

246



### 247 3. Results

248

#### 249 3.1 *Fish growth, feed utilisation and survival*

250 Fish in this study generally grew at an equivalent rate to those reported in Codabaccus et al.  
251 (2012), and at a better rate than those reported by Miller et al. (2007), despite being pair-fed in the  
252 present study and to apparent satiety in the other studies. A significant effect of dietary fatty acid  
253 composition on growth (as final weight, weight gain and gain rate) after 9-weeks was observed (Table  
254 4a and 4b). No significant differences were seen among the different DHA inclusion levels when  
255 analysed using regression (Table 4a), but fish fed diet D10E had significantly better growth than fish  
256 fed the diets with the two lower and the two higher DHA inclusion levels (Table 4b). Interestingly,  
257 during this period of growth the fish fed the D10A treatment was best.

258 As intended, there were no significant differences in feed intake among any of the treatments  
259 (Table 4a,b). Some significant differences among the treatments for FCR were observed. Both of the  
260 EPA treatments showed significantly lower FCR than the lower DHA inclusion levels (D1 and D5).  
261 No significant improvements in FCR were noted with increasing DHA inclusion based on regression  
262 analysis (Table 4a). No other significant differences in FCR were present.

263 No significant effects of treatment on survival were noted with increasing DHA content when  
264 based on regression, albeit  $P = 0.060$ ). Fish fed the D10A treatment had the poorest survival of all  
265 treatments but, despite a difference of 11 % between this treatment and the treatment with highest  
266 survival (D5E), variability among replicates meant this was not significantly different (Table 4).  
267 However, notable were both the consistent decline in survival of fish in the D10A treatment and the  
268 sudden decline in survival from day 40 onwards, prior to the day 42 weighing event, in fish fed D1.

269

#### 270 3.2 *Tissue composition and fatty acid retention*

271 The fatty acid composition of fish largely reflected that of the dietary treatments (Table 5). As  
272 expected there was an increasing percentage of DHA in the tissues of fish fed increasing dietary DHA  
273 content. However, the concentration of DHA was typically always marginally higher than that of the  
274 diet. Somatic EPA content declined substantially from the initial fish in all treatments and at the end  
275 of the experiment represented around 3 % of total fatty acids (Table 5). Even with the treatment  
276 containing a higher level of added EPA it still only represented 4 % of the total fatty acids. Somatic  
277 ARA was low in fish fed all treatments ( $< 1\%$ ) except for fish fed diet D10A where it increased to  
278 around 3 % of the total fatty acids in the fish (Table 5). Total SFA content of fish at the end of the  
279 experiment was generally very consistent at around 30 % of total fatty acids (range 29 – 32 % of total  
280 fatty acids). MUFA content of fish from each of the treatments ranged from 35 % in the initial  
281 population sample to 51 % in fish fed the D5 treatment. Among most treatments there was more  
282 variation in MUFA content than the SFA content (range 44 % to 51 %). The proportions of total LC-  
283 PUFA in the whole body tissues of the treatment diet fed fish varied from 11 % to 17 %. It was

284 highest in the treatment fed the D20 diet and lowest in the fish fed the D5 diet. However, the initial  
285 fish had the highest LC-PUFA content of all at 23% of total fatty acids. There was only a minor  
286 treatment effect in whole body content of LC-PUFA with increasing DHA inclusion in the diet (range  
287 11% to 17%). Even the lowest inclusion level of LC-PUFA (the D1 diet) was relatively conserved at a  
288 total LC-PUFA level of 12% of total fatty acids.

289         There was considerable difference in the fatty acid deposition efficiencies of the different  
290 PUFA and LC-PUFA. DHA deposition efficiency was the most dramatically affected by DHA  
291 inclusion level, but not by the inclusion of either EPA or ARA in the diet. At the lowest inclusion  
292 level of DHA the deposition efficiency exceeded 300 %, but as DHA inclusion increased there was a  
293 curvilinear decline in deposition efficiency such that at the next inclusion level of DHA (D5) retention  
294 had declined to around 58 % and by the highest DHA inclusion level (D20) the deposition efficiency  
295 had declined to just over 30 % (Fig. 1a).

296         The deposition efficiency of EPA was clearly affected by DHA inclusion level, and also by  
297 the inclusion of either EPA or ARA in the diet. At the lowest inclusion level of DHA, negative  
298 deposition efficiencies of EPA were observed. Deposition efficiency of EPA increased in a curvilinear  
299 fashion with increasing DHA in the diet before declining again to negative deposition efficiency at the  
300 highest DHA inclusion (Fig. 1b). However, among the D10, D10A and D10E diets there were marked  
301 differences. Addition of ARA reduced EPA deposition efficiency to -18 %, while inclusion of EPA or  
302 DHA increased it to 18 % or 28 %, respectively.

303         In contrast, the deposition efficiencies of ARA, LNA and LOA were largely unaffected by  
304 DHA inclusion level with, in most cases, a consistent level of retention of each of the respective fatty  
305 acids. However, the level of retention of each fatty acid varied substantially among each other. Thus,  
306 ARA retention was generally high at around 180 %, and addition of EPA or ARA to the diet at the 10  
307 g/kg inclusion level reduced ARA retention to around 40% (Fig. 1c). The lower inclusion level of  
308 EPA had little effect on the efficiency of ARA retention. Deposition efficiency of LNA was also  
309 largely unaffected by DHA inclusion level (Fig. 2a). Although there was some variation in the LNA  
310 deposition efficiency there were no consistent patterns in response to DHA dose, or EPA or ARA  
311 inclusion. Similarly, deposition efficiency of LOA was also unaffected by DHA inclusion level, or the  
312 inclusion of ARA or EPA in the diet (Fig. 2b).

313

### 314 3.3 *Fish behaviour*

315         There were some significant differences among the treatments in the assessed behaviour  
316 indices (Fig. 3a,b). There was a relatively clear and significant dose response effect between both  
317 behavioural indices and the DHA content of the diet. The effect was most obvious with the more  
318 subjective assessment of a behaviour score, but these results were a direct inverse reflection of the  
319 completely objective assessment based on the proportion of pellets remaining after a defined feeding  
320 period. Both the EPA treatments (D10E and D5E) and the ARA treatment (D10A) showed improved

321 behaviours relative to the low LC-PUFA diet (D1), although these effects could not be fully  
322 discriminated from dietary DHA content.

323

#### 324 3.4 *Plasma chemistry*

325 There were several significant differences among the plasma chemistry parameters relative to  
326 dietary treatment (Table 6). Only those parameters that showed significant effects that could be  
327 clearly attributed to dietary treatment are discussed below.

328 There was a significant increase in plasma activities of the liver marker enzymes, alanine  
329 aminotransferase and asparagine aminotransferase, with the inclusion of ARA in the diet, but varying  
330 the levels of DHA or inclusion of EPA had little or no effect on their activities. Although there were  
331 significant differences in activities of glutamate dehydrogenase among the treatments a consistent  
332 pattern was not clearly observed. Creatinine levels were not significantly influenced by the level of  
333 DHA in the diet, but were significantly affected by the inclusion of ARA or EPA. Plasma calcium  
334 levels were significantly different among the treatments with a pattern suggesting a trend towards  
335 lower concentrations with increasing dietary DHA. The addition of EPA to the diet increased plasma  
336 calcium to significantly greater levels than those in fish fed the equivalent diet with DHA, though  
337 addition of ARA did not have the same effect. Plasma cholesterol levels were higher in fish fed the  
338 diet D10E. Red blood cell counts showed a significant suppression in the ARA treatment relative to  
339 the EPA treatment and also some of the DHA treatments but there did not appear to be a dose  
340 response to dietary DHA.

341

#### 342 3.5 *Physical health assessment*

343 A range of physical pathology signs were assessed at week 9 (Table 7). It was notable that  
344 fish fed the low LC-PUFA diet (D1) showed few signs of physical pathologies. Increasing dietary  
345 DHA initially increased signs of physical pathology (D5 and D10) but these declined at higher levels  
346 (D15 and D20). The only notable effects attributable to EPA or ARA inclusion were increased  
347 incidence of pectoral fin erosion (D10E) or scale-damage (D10A).

348

349

## 350 4. Discussion

351

### 352 4.1 What is so essential about essential fatty acids?

353 The results from the present study provide empirical evidence of the roles of DHA and DHA  
354 in combination with either EPA or ARA in the diets of Atlantic salmon. Despite much evidence of the  
355 essentiality of dietary n-3 LC-PUFA, the present results suggest that the essentiality is relatively  
356 minor in salmon. However, the findings support that, while DHA alone can satisfy most requirements,  
357 the addition of EPA stimulates performance on a range of levels beyond that achieved with DHA  
358 alone. This suggests that EPA plays an equally important role in lipid metabolism in this species.  
359 Notably, dietary EPA along with DHA promotes better growth and health than that achieved by the  
360 same level of DHA alone suggesting potential of distinct roles for each LC-PUFA. It was also shown  
361 that the inclusion of ARA in addition to DHA had little effect on growth, but had effects on animal  
362 health. The outcomes of the present study in salmon were generally consistent to those reported in a  
363 similar study with Asian seabass (*barramundi*), although the current study also showed distinct  
364 differences, particularly in regards to the clinical observations (Glencross and Rutherford, 2011).  
365 These findings raise the question of why such differences between Atlantic salmon and Asian sea bass  
366 were observed and whether they relate to the environmental preferences/lifecycle of each species. To  
367 address this question it is pertinent to first consider the effects in relation to previous research in this  
368 area to examine why some findings were different and others similar.

369 It had been reported that the dietary requirement of salmonids for n-3 LC-PUFA was in the  
370 range from 10 g/kg to 25 g/kg of the diet depending on species and experimental conditions (see  
371 Glencross, 2009). The first comprehensive series of studies on EFA requirements of a salmonid were  
372 those of Castell et al. (1972a, b) with rainbow trout (*Oncorhynchus mykiss*). In those early studies,  
373 fish were fed one of four diets in which treatments included a fat-free diet, a diet in which the 50 g/kg  
374 lipid in the diet was provided as 18:1n-9, a diet with 40 g/kg 18:1n-9 and 10 g/kg LOA, and a diet  
375 with 40 g/kg 18:1n-9 and 10 g/kg LNA. The results of this work demonstrated that salmonids had a  
376 defined n-3 requirement, albeit as LNA in this case. However, the value of LNA as an EFA for trout  
377 was proposed to exist only because it had significant ability to desaturate and elongate LNA to the  
378 biologically active LC-PUFA, EPA and DHA (Tocher, 2003). In the present study it was interesting  
379 to note that the fish fed the D1 diet (albeit not completely devoid of LC-PUFA) showed relatively  
380 good survival and growth. Indeed classic signs of EFA deficiency were not observed even after 62  
381 days of the experiment. However, the most obvious feature of fish fed that diet was the sudden decline  
382 in performance after about 40 days. If the initial decline in survival around day 7 is discounted  
383 (probably due to handling losses) then the effects observed on survival in this experiment are even  
384 more telling. The results provide good support that the fish were relying on endogenous stores of LC-  
385 PUFA during this initial period before levels reached critical limits. Interestingly, if the growth  
386 response to DHA dose is examined solely from week 6 onwards a much clearer response to DHA can

387 be observed, which further affirms the notion of a requirement for this fatty acid and also that the  
388 optimal requirement level is around 10 g/kg. In retrospect it would have been of value to have  
389 continued this study for longer to allow these effects to consolidate.

390 Over the past decades, since the foundation work of Castell (1972a, b), there have been  
391 further studies to ascertain what the critical requirement (quantitative or qualitative) might be for the  
392 n-3 LC-PUFA, EPA and DHA, in salmonid species (Brodtkorb et al., 1997; Ruyter et al., 2000a,b).  
393 An important methodological point of difference in the present study, compared to previous studies,  
394 was the use of a pair-fed feeding regime to isolate other nutrient intake effects. In using this strategy  
395 we have demonstrated that the requirement for DHA by Atlantic salmon is relatively minor, and have  
396 been able to isolate the confounding effects of feed intake variability and thereby remove protein and  
397 energy intake effects from the interpretation.

398 It has also been previously reported that an excess amount of n-3 LC-PUFA in the diet can  
399 have an adverse effect on growth and food utilization by fish. An increase in EPA or DHA content to  
400 four-times the proposed requirement level reportedly resulted in poorer growth and feed efficiency,  
401 and the fish showed signs of EFA deficiency (Takeuchi and Watanabe, 1976). However, almost every  
402 modern salmonid diet tends to have lipid levels almost double those used in the 1970's and 1980's  
403 and, until recently, dilution of fish oil with alternatives (largely vegetable oils), these diets also had  
404 EPA + DHA inclusion levels considerably above the reported threshold without the apparent negative  
405 effects of inclusion of high amounts of n-3 LC-PUFA reported previously (Takeuchi and Watanabe,  
406 1976; Yu and Sinnhuber, 1976; 1979). However, some recent studies have demonstrated that high  
407 inclusion levels of LC-PUFA can have a significant negative effect on fish performance and health  
408 (Ruyter et al., 2000a; Ostbye et al., 2011; Betancor et al., 2011; Glencross and Rutherford, 2011). In  
409 the present study, such negative effects with the highest inclusion level of DHA, or a similar LC-  
410 PUFA inclusion level of EPA and DHA, did not result in increased mortalities, levels of physical  
411 pathologies, or aberrations in plasma biochemistry or haematology.

412 Formative studies by Ruyter et al. (2000a,b) used a series of trials on Atlantic salmon fry to  
413 determine their quantitative (0, 1, 2, 5, 10 and 20 g/kg of the diet) and qualitative requirements for  
414 LOA, LNA, and EPA and DHA in combination. These diets had relatively low lipid levels (~80 g/kg)  
415 in which the inclusion of LNA, and EPA and DHA in combination both provided significant benefits  
416 to the fish. The combination of EPA and DHA at 12.5 % total fatty acids provided the greatest benefit  
417 of all the treatments studied. While the data generally support this, the effects observed in the present  
418 study with post-smolt Atlantic salmon were not as dramatic.

419

#### 420 4.2 *Fish growth and feed utilisation*

421 The growth of the fish in the present study, using the pair-fed regime, demonstrated that the  
422 stimulatory effect of DHA is minor at best. Indeed, although addition of EPA to the diet produced a  
423 significant improvement in growth relative to that observed in fish fed the low LC-PUFA diet, the

424 effect was still not as pronounced as that reported in some other species (reviewed by Glencross,  
425 2009). However, this observation showed that, while DHA may be important to development in this  
426 species, it cannot be provided in exclusion to EPA and indeed low levels of dietary LNA may be  
427 sufficient to offset the requirements for either LC-PUFA based on the fact that Atlantic salmon has  
428 demonstrated capacity for endogenous LC-PUFA biosynthesis (Tocher et al., 2003). However, despite  
429 evidence of the importance of dietary EPA in addition to DHA, further exploration of the relationship  
430 between the n-3 LC-PUFA and the importance of the ratios between these key PUFA is required  
431 (Furuita et al., 1998).

432 A potential negative aspect of using a pair-fed feeding regime though is that the fish will  
433 grow somewhat slower than that expected of fish fed to satiety. However, in the present experiment  
434 the growth rates of the fish were equal to or better than that of Atlantic salmon parr and post-smolt fed  
435 to satiety in other recently published works (Miller et al., 2007; Codabaccus et al., 2012). Ironically  
436 the fish in the present study doubled their weight in 62 days compared with those in the study of  
437 Codabaccus et al. (2012) which doubled their weight from 71 g to 148 g in 75 days. However,  
438 consistent with the present study, Codabaccus et al. (2012) also found limited influence of the fatty  
439 acid composition on the growth or feed utilisation by post-smolt Atlantic salmon. These authors also  
440 stated that varying the ratio of EPA to DHA had no significant effect on growth or feed utilisation in  
441 post-smolt Atlantic salmon. Other studies with Atlantic salmon have shown that fish grew best with  
442 an inclusion of 10 g/kg LC-PUFA in their diet, when this was provided as an equal ratio of EPA to  
443 DHA (Ruyter et al., 2000a). Rainbow trout also grew best with an EPA to DHA ratio of 1 : 1, but with  
444 a total LC-PUFA inclusion level of 3 g/kg (Watanabe and Takeuchi, 1976). However, these authors  
445 also reported that EPA could be omitted from the diet and the LC-PUFA supplied solely as DHA to  
446 achieve the same effect (Watanabe and Takeuchi, 1976). Arguably this might also be possible with  
447 Atlantic salmon based on the present results, although the marginal improvements in performance  
448 observed with both EPA and DHA in the diet suggested both these LC-PUFA are possibly required.

449

#### 450 4.3 *Tissue composition and fatty acid retention*

451 The changes in tissue fatty acid composition of fish fed each diet were consistent with those  
452 reported in most other studies on fish fed different lipid sources in that the tissue fatty acids were  
453 largely reflective of the respective diets (Sargent et al., 1999). However, it is the subtleties around the  
454 examination of the mass-balance relationship between dietary and tissue fatty acid compositions  
455 through the analysis of the deposition efficiency that often show distinct differences in the utilisation  
456 of different dietary fatty acids, particularly in the case of DHA intake (Glencross et al., 2003;  
457 Glencross and Rutherford, 2011).

458 The observation that DHA deposition efficiency decreased with increasing dietary DHA were  
459 consistent with other reports on utilisation of this fatty acid (Glencross et al., 2003; Glencross and  
460 Rutherford, 2011). At the lowest inclusion level (1 g/kg) the very high deposition efficiency (>300%)

461 suggested that there was high conservation and/or possible endogenous synthesis of DHA (Glencross  
462 et al., 2003; Turchini and Francis, 2009). Certainly it is well established that Atlantic salmon have this  
463 capability (Tocher et al., 2003; Thomassen et al., 2012). The negative deposition efficiency values of  
464 EPA at both low and high DHA levels supports the position that some chain elongation and  
465 desaturation of precursor fatty acids occurred, but this pattern of EPA deposition efficiency contrasts  
466 with that observed in a similar study on Asian sea bass where there was clear retroconversion of DHA  
467 to produce EPA (Glencross and Rutherford, 2011). However, the curvilinear response in EPA  
468 deposition efficiency, peaking at a DHA inclusion level of 10 g/kg, is perhaps also supportive of  
469 defining the optimal dietary inclusion level of DHA. As expected, the addition of EPA to the diet  
470 resulted in relatively low deposition efficiency of EPA, but the addition of ARA to the diet produced  
471 an even more interesting response in that it also induced a negative deposition efficiency of EPA. This  
472 may be attributable to an increase in flux of EPA in the eicosanoid pathways, the activity of which  
473 may have been heightened by the additional dietary ARA (Bell et al., 1995; Ghioni et al., 2002).  
474 Notably there is a distinct symmetry in EPA retention between EPA and ARA diets, and this  
475 counteractive concentration/response effect has been noted in other species (Xu et al., 2010). The  
476 deposition efficiency of ARA was substantially higher (~180 %) than that reported in the counterpart  
477 study (~120 %) with Asian sea bass (Glencross and Rutherford, 2011). ARA retention in Atlantic  
478 salmon was largely unaffected by DHA inclusion, although the addition of EPA or ARA to the diet at  
479 the 10 g/kg inclusion level resulted in a significant reduction in ARA retention to around 40 %,  
480 although there were few effects of varying DHA inclusion level. This observation on ARA retention  
481 contrasts with the competing symmetry effect noted for EPA deposition efficiency with EPA and  
482 ARA inclusion.

483         The absence of any clear dose response effects of DHA on LNA (or LOA) deposition  
484 efficiency suggested that this C18 PUFA appeared to be playing a limited role in DHA supply through  
485 possible elongation and desaturation processes. This may be being restricted by the relatively low  
486 levels of LNA in the diet (<1% of total fatty acids).

487

#### 488 4.4 *Fish behaviour*

489         Previous studies on DHA dose response effects in Asian sea bass reported some distinct  
490 behavioural elements attributed to DHA (Glencross and Rutherford, 2011). Therefore, feeding  
491 behaviour was examined in the present study to determine if there was also a dose-response effect of  
492 DHA in Atlantic salmon. Although salmon were more skittish in their behaviour compared to Asian  
493 sea bass, a relative change in behaviour was still noted among the different DHA treatments. In the  
494 present study, the complications in the behavioural assessment compared to that done in Asian sea  
495 bass (Glencross and Rutherford, 2011) required both a reassessment of the behaviour score  
496 parameters and also an additional, more objective, feeding behaviour assessment and, combined, they  
497 provide confidence in our interpretation. Both methods showed that positive feeding behaviour

498 responded in a dose-response manner to increasing inclusion of DHA. This effect could not be  
499 attributed to either EPA or ARA as the inclusion of DHA in each of the diets clearly accounted for the  
500 responses observed and the addition of the other LC-PUFA did not alter these responses. Whether this  
501 effect was via changes to brain function or visual development is unclear, but further analysis of brain  
502 and eye compositions of fish from such a dose-response design may help clarify this issue (Tocher  
503 and Harvie, 1988; Crawford, 1992; Brodtkorb et al., 1997). Interestingly, earlier work had more  
504 strongly implicated dietary EPA as having a greater influence on the composition of lipids in neural  
505 tissues, though an effect of DHA was also noted (Mourente and Tocher, 1992; Brodtkorb et al., 1997).

506

#### 507 4.5 *Fish health and plasma chemistry*

508 There have been many reports examining the effects of LC-PUFA (both n-3 and n-6) on the  
509 health of fish (Thompson et al., 1996; Richard et al., 2007; Ostbye et al., 2009; Betancor et al., 2011).  
510 In the present study, the focus was on both a clinical assessment of physical signs of EFA deficiency  
511 (poor growth, lesions, fin erosion) and also measurement of biochemical markers in plasma. Most  
512 notable was the response to dietary ARA as indicated by increased scale damage/skin lesions. The  
513 reduction in the level of fin damage with increasing levels of n-3 LC-PUFA was consistent with other  
514 studies, although the relatively low levels of fin damage in the low LC-PUFA diet (D1) were perhaps  
515 surprising (Castell, 1972a, b; Ruyter et al., 2000a).

516 The plasma biochemical markers perhaps provided a more objective assessment of the roles  
517 of DHA, EPA and ARA in fish health, and in particular liver function (Glencross and Rutherford,  
518 2011). However, the number of treatments and tests involved meant that significant, but clinically  
519 irrelevant, effects may be observed and, therefore, the focus was on effects related to dose response,  
520 or relative response to corresponding inclusion of different LC-PUFA. Notably, the present study with  
521 Atlantic salmon showed a contrasting result to osmotic balance issues observed previously in Asian  
522 sea bass in the relative absence of EPA in the diet (Glencross and Rutherford, 2011). In Atlantic  
523 salmon there was little evidence of perturbations in urea, potassium or chloride levels. This suggested  
524 that EPA, which plays an important role in regulating plasma osmolarity through eicosanoid  
525 metabolism, was not particularly restricted in this study (Henderson et al., 1985; Beckman and  
526 Mustafa, 1992). This could be a sign that EPA requirements for Atlantic salmon are either low, or that  
527 endogenous biosynthesis was sufficient to maintain homeostasis.

528 More notable in the present experiment though were the changes in liver enzyme markers  
529 such alanine aminotransferase, which showed an acute response to the presence of ARA, but was less  
530 responsive to the inclusion of DHA or EPA. Other liver marker enzymes such as glutamate  
531 dehydrogenase, however, also showed a dose response to dietary DHA, whilst still being elevated by  
532 ARA inclusion. Inclusion of EPA resulted in a lower level of this enzyme activity in the plasma.  
533 These observations provide some support to negative effects of ARA and DHA at high inclusion  
534 levels (in the absence of EPA) on the liver health of this species.



535

#### 536 4.6 *Implications and conclusions*

537 The present study showed that Atlantic salmon were not highly sensitive to dietary LC-PUFA  
538 manipulation and could perform relatively well with only low dietary levels of these fatty acids.  
539 However, the data indicated that dietary inclusion of 10 g/kg or above of DHA generally improved  
540 growth, feed conversion and feeding behaviour compared to fish fed a diet with 1 g/kg of DHA, albeit  
541 not all parameters were consistently significant. It was notable that the addition of EPA to the diet  
542 resulted in further improvements to growth and feed conversion, but did not appear to have an impact  
543 on feeding behaviour. In contrast to the results observed in similar studies, the absence of EPA in the  
544 diet did not induce any major pathologies (Glencross and Rutherford, 2011). Therefore, it is  
545 recommended, based on these findings, that at least 10 g/kg of DHA are required for optimal  
546 performance, but that 20 g/kg of EPA + DHA is preferable. Further investigation of whether the ratio  
547 of EPA to DHA can be altered and still achieve similar performance is required.

548

#### 549 **Acknowledgements**

550

551 The assistance of Giles Campbell with the feed extrusion at CSIRO is gratefully acknowledged.  
552 Thanks also to Fiona Strachan, James Dick, Matthew Sprague, Graeme McWhinnie, William Roy and  
553 Simon Barnett from the University of Stirling for technical assistance. Thanks to Katherine Morton  
554 for editorial comment on an early draft manuscript of this work. We also acknowledge the support of  
555 the OECD Cooperative Research Program for supporting the travel and subsistence of BDG in  
556 Scotland during this work.

557

#### 558 **References**

559

560 Ackman R.G., 1980. Fish lipids. J.J. Connell (Ed.). In: *Advances in Fish Science and Technology*, pp.  
561 87-103. Fishing News Books, Farnham.

562

563 AOAC, 2000. *Official Methods of Analysis*. Association of official analytical chemist. Washington,  
564 D.C., USA.

565

566 Beckman, B., Mustafa, T., 1992. Arachidonic acid metabolism in gill homogenate and isolated gill  
567 cells from rainbow trout, *Oncorhynchus mykiss*: The effect of osmolarity, electrolytes and prolactin.  
568 *Fish Physiology and Biochemistry* 10, 213-222.

569

570 Bell, M.V., Henderson, R.J., Sargent, J.R., 1986. The role of polyunsaturated fatty acids in fish.  
571 *Comparative Biochemistry and Physiology* 83B, 711-719.

572  
573 Bell, J.G., Youngson, A., Mitchell, A.I., Cowey, C.B., 1989. The effect of enhanced intake of linoleic  
574 acid on the fatty acid composition of tissue polar lipids of post smolt Atlantic salmon (*Salmo salar*).  
575 *Lipids* 24, 240-242.  
576  
577 Bell, J.G., Castell, J.D., Tocher, D.R., MacDonald, F.M., Sargent, J.R., 1995. Effects of different  
578 dietary arachidonic acid:docosahexaenoic acid ratios on phospholipid fatty acid compositions and  
579 prostaglandin production in juvenile turbot (*Scophthalmus maximus*). *Fish Physiol. Biochem.* 14, 139-  
580 151.  
581  
582 Betancor, M.B., Atalah, E., Caballerro, M.J., Benitez-Santana, T., Roo, J., Montero, D., Izquierdo, M.  
583 A., 2011.  $\alpha$ -Tocopherol in weaning diets for European sea bass (*Dicentrarchus labrax*) improves  
584 survival and reduces tissue damage caused by excess dietary DHA contents. *Aquaculture Nutrition*  
585 17, e112-c122.  
586  
587 Brodtkorb, T., Rosenlund, G., Lie, O., 1997. Effects of dietary levels of 20:5n-3 and 22:6n-3 on tissue  
588 lipid composition in juvenile Atlantic salmon, *Salmo salar*, with emphasis on brain and eye.  
589 *Aquaculture Nutrition* 3, 175-187.  
590  
591 Castell, J.D., Sinnhuber, R.O., Wales, J.H., Lee, J.D., 1972a. Essential fatty acids in the diet of  
592 rainbow trout (*Salmo gairdneri*): Growth, feed conversion and some gross deficiency symptoms.  
593 *Journal of Nutrition* 102, 77-86.  
594  
595 Castell, J.D., Sinnhuber, R.O., Wales, J.H., Lee, J.D., 1972b. Essential fatty acids in the diet of  
596 rainbow trout (*Salmo gairdneri*): Physiological symptoms of EFA deficiency. *Journal of Nutrition*  
597 102, 87-92.  
598  
599 Castell, J.D., Bell, J.G., Tocher, D.R., Sargent, J.R., 1994. Effects of purified diets containing  
600 different combinations of arachidonic and docosahexaenoic acid on survival, growth and fatty acid  
601 composition of juvenile turbot (*Scophthalmus maximus*). *Aquaculture* 128, 315-333.  
602  
603 Christie, W.W., 2003. Preparation of derivates of fatty acids, p.205-225. In W.W. Christie, *Lipid*  
604 *Analysis: isolation, separation and structural analysis of lipids*. 3rd ed. J. Barnes and Associates.  
605  
606 Codabaccus, B., Carter, C.G., Bridle, A.R., Nichols, P.D., 2012. The “n-3 LC-PUFA sparing effect”  
607 of modified dietary n-3 LC-PUFA content and DHA to EPA ratio in Atlantic salmon smolt.  
608 *Aquaculture* 356-357, 135-140.

609  
610 Folch, J., Lees, M., Sloane-Stanley, G.H., 1957. A simple method for the isolation and purification of  
611 total lipids from animal tissues. *J. Biol. Chem.* 226, 497-509.  
612  
613 Garg, M.L., Li, T., 1994. The importance of dietary eicosapentaenoic to docosahexaenoic acid ratio in  
614 modulation of serum lipid and arachidonic acid levels. *Nutrition Research* 14, 1575-1582.  
615  
616 Garg, M. L., Thomson, A.B.R., Clandinin, M.T., 1990. Interactions of saturated, n-6 and n-3  
617 polyunsaturated fatty acids to modulate arachidonic acid metabolism. *Journal of Lipid Research* 31,  
618 271-277.  
619  
620 Ghioni, C., Porter, A.E.A, Taylor, G.W., Tocher, D.R. 2002. Metabolism of 18:4n-3 (stearidonic acid)  
621 and 20:4n-3 in salmonid cells in culture and inhibition of the production of prostaglandin F2 $\alpha$   
622 (PGF2 $\alpha$ ) from 20:4n-6 (arachidonic acid). *Fish Physiology and Biochemistry* 27, 81-96.  
623  
624 Glencross, B.D., 2009. Exploring the nutritional demand for essential fatty acids by aquaculture  
625 species. *Reviews in Aquaculture* 1, 71-124.  
626  
627 Glencross, B.D., Rutherford, N.R., 2011. The docosahexaenoic acid (DHA) requirements of juvenile  
628 barramundi (*Lates calcarifer*). *Aquaculture Nutrition* 17, e536-e548.  
629  
630 Glencross, B.D., Hawkins, W.E., Curnow, J.G., 2003. Restoration of the fatty acid composition of red  
631 seabream (*Pagrus auratus*) after grow-out on plant oil based diets. *Aquaculture Nutrition* 9, 409-418.  
632  
633 Glencross, B.D., Carter, C.G., Duijster, N., Evans, D.E., Dods, K., McCafferty, P., Hawkins, W.E.,  
634 Maas, R., Sipsas, S., 2004. A comparison of the digestive capacity of Atlantic salmon (*Salmo salar*)  
635 and rainbow trout (*Oncorhynchus mykiss*) when fed a range of plant protein products. *Aquaculture*  
636 237, 333-346.  
637  
638 Glencross, B.D., Blyth D., Tabrett, S.J., Bourne, N., Irvin, S., Fox-Smith, T., Smullen, R.P., 2012. An  
639 examination of digestibility and technical qualities of a range of cereal grains when fed to juvenile  
640 barramundi (*Lates calcarifer*) in extruded diets. *Aquaculture Nutrition* 18, 388-399.  
641  
642 Helland, S., Grisdale-Helland, B., Nerland, S., 1996. A simple method for the measurement of daily  
643 feed intake of groups of fish in tanks. *Aquaculture* 139, 156-163.  
644

645 Henderson, R.J., Bell, M.V., Sargent, J.R., 1985. The conversion of polyunsaturated fatty acids to  
646 prostaglandins by tissue homogenates of turbot, *Scophthalmus maximus*. Journal of Experimental  
647 Marine Biology and Ecology 85, 93-99.  
648

649 Leaver, M.J., Bautista, J.M., Bjornsson, B.T., Jonsson, E., Krey, G., Tocher, D.R., Torstensen, B.E.,  
650 2008. Towards fish lipid nutrigenomics: current state and prospects for fin-fish aquaculture. Reviews  
651 in Fisheries Science 16, 71-92.  
652

653 Miller, M.R., Nichols, P.D., Carter, C.G., 2007. Replacement of fish oil with thraustochytrid  
654 Schisochytrium sp. oil in Atlantic salmon parr (*Salmo salar* L.) diets. Comparative Biochemistry and  
655 Physiology – Part A 148, 382-392.  
656

657 Mourente, G., Tocher, D.R., 1991. Specific accumulation of docosahexaenoic acid (22:6n-3) in brain  
658 lipids during development of juvenile turbot, *Scophthalmus maximus*. Lipids 26, 871-877.  
659

660 O'Fallon, J.V., Busboom, J.R., Nelson, M.L., Gaskins, C.T., 2007. A direct method for fatty acid  
661 methyl ester (FAME) synthesis: Application to wet meat, tissues, oils and feedstuffs. Journal of  
662 Animal Science 85, 1511-1522.  
663

664 Ostbye, T.K., Kjaer, M.A., Rora, A.M.B., Torstensen, B., Ruyter, B., 2011. High n-3 HUFA levels in  
665 the diet of Atlantic salmon affect muscle and mitochondrial membrane lipids and their susceptibility  
666 to oxidative stress. Aquaculture Nutrition 17, 177-190.  
667

668 Petrie, J.R., Shrestha, P., Zhou, X.R., Mansour, M.P., Liu, Q., Belide, S., Nichols, P.D., Singh, S.P.,  
669 2012. Metabolic engineering plant seeds with fish oil-like levels of DHA. PLOS One 7, e49165.  
670

671 Rinchar, J., Czesny, S., Dabrowski, K., 2007. Influence of lipid class and fatty acid deficiency on  
672 survival, growth, and fatty acid composition in rainbow trout juveniles. Aquaculture 264, 363-371.  
673

674 Ruyter, B., Rosjo, C., Einen, O., Thomassen, M.S., 2000a. Essential fatty acids in Atlantic salmon:  
675 effects of increasing dietary doses of n-3 and n-6 fatty acids on growth, survival and fatty acid  
676 composition of liver, blood and carcass. Aquaculture Nutrition 6, 119-127.  
677

678 Ruyter, B., Rosjo, C., Einen, O., Thomassen, M.S., 2000b. Essential fatty acids in Atlantic salmon:  
679 time course of changes in fatty acid composition of liver, blood and carcass induced by a diet  
680 deficient in n-3 and n-6 fatty acids. Aquaculture Nutrition 6, 109-117.  
681

682 Sales, J., Glencross, B., 2011. A meta-analysis of the effects of dietary marine oil replacement with  
683 vegetable oils on growth, feed conversion and muscle fatty acid composition of fish species.  
684 Aquaculture Nutrition 17, e271-e287.  
685  
686 Tacon, A.G.J., Metian, M., 2008. Global overview on the use of fish meal and fish oil in industrially  
687 compounded aquafeeds: Trends and future prospects. Aquaculture 285, 146–158  
688  
689 Takeuchi, T., Watanabe, T., 1976. Nutritive value of  $\omega$ 3 highly unsaturated fatty acids in pollock liver  
690 oil for rainbow trout. Bulletin of Japanese Society of Scientific Fisheries 42, 907-919.  
691  
692 Taylor, R.S., Muller, W.J., Cook, M.T., Kube, P.D., Elliott, N.G., 2009. Gill observations in Atlantic  
693 salmon (*Salmo salar*, L.) during repeated amoebic gill disease (AGD) field exposure and survival  
694 challenge. Aquaculture 290, 1-8.  
695  
696 Terano, T., Salmon, J.S., Higgs, G.A., Moncada, S., 1986. Eicosapentaenoic acid as a modulator of  
697 inflammation – effect on prostaglandin and leukotriene synthesis. Biochemical Pharmacology 35,  
698 779-785.  
699  
700 Thomassen, M.S., Rein, D., Berge, G.M., Ostbye, T.K., Ruyter, B., 2012. High dietary EPA does not  
701 inhibit  $\Delta$ 5 and  $\Delta$ 6 desaturases in Atlantic salmon (*Salmo salar* L.) fed rapeseed oil diets. Aquaculture  
702 360-361, 78-85.  
703  
704 Thompson, K.D., Tatner, M.F., Henderson, R.J. 1996. Effects of dietary (n-3) and (n-6)  
705 polyunsaturated fatty acid ratio on the immune response of Atlantic salmon (*Salmo salar* L.).  
706 Aquaculture Nutrition 2, 21-31.  
707  
708 Tocher, D. R. 2003. Metabolism and functions of lipids and fatty acids in teleost fish. Rev. Fisheries  
709 Sci. 11, 107-184.  
710  
711 Tocher, D.R., Harvie, D.G., 1988. Fatty acid compositions of the major phosphoglycerides from fish  
712 neural tissues; n-3 and n-6 polyunsaturated fatty acids in rainbow trout (*Salmo gairdneri*) and cod  
713 (*Gadus morhua*) brains and retinas. Fish Physiology and Biochemistry 5, 229-239.  
714  
715 Tocher, D.R., Agaba, M., Hastings, N., Teale, A.J., 2003. Biochemical and molecular studies of the  
716 polyunsaturated fatty acid desaturation pathway in fish. In: The Big Fish Bang. Proceedings of the

717 26th Annual Larval Fish Conference (H.I. Browman and A.B. Skiftesvik Eds.) Institute of Marine  
718 Research, Bergen, Norway. pp 211-227.  
719  
720 Turchini, G.M., Francis, D.S., 2009. Fatty acid metabolism (desaturation, elongation and  $\beta$ -  
721 oxidation) in rainbow trout fed fish oil- or linseed oil-based diets. *British Journal of Nutrition* 102, 69-  
722 81.  
723  
724 Villalta, M., Estevez, A., Bransden, M.P., Bell, J.G., 2008. Arachidonic acid,  
725 arachidonic/eicosapentaenoic acid ratio, stearidonic acid and eicosanoids are involved in dietary-  
726 induced albinism in Senegal sole (*Solea senegalensis*). *Aquaculture Nutrition* 14, 120-128.  
727  
728 Xu, H., Ai, Q., Mai, K., Xu, W., Wang, J., Ma, H., Zhang, W., Wang, X., Liufu, Z., 2010. Effects of  
729 dietary arachidonic acid on growth performance, survival, immune response and tissue fatty acid  
730 composition of juvenile Japanese seabass, *Lateolabrax japonicus*. *Aquaculture* 307, 75-82.  
731  
732 Yu, T.C., Sinnhuber, R.O., 1976. Growth response of rainbow trout (*Salmo gairdneri*) to  
733 dietary  $\omega$ 3 and  $\omega$ 6 fatty acids. *Aquaculture* 8, 309-317.  
734  
735 Yu, T.C., Sinnhuber, R.O., 1979. Effect of dietary  $\omega$ 3 and  $\omega$ 6 fatty acids on growth and  
736 feed conversion efficiency of coho salmon (*Oncorhynchus kisutch*). *Aquaculture* 16, 31-  
737 38.  
738

739 **Figure legends**

740

741 Figure 1. Deposition efficiency (%) of DHA (a), EPA (b) and ARA (c) in fish from each of the  
742 experimental treatments. Treatments are indicated by (●) for those diets with  
743 incremental inclusion levels of DHA. Those diets with equivalent amounts of EPA (○)  
744 and ARA (Δ) are also indicated. Error bars show the pooled SEM.

745

746 Figure 2. Deposition efficiency (%) of LNA (a) and LOA (b) in fish from each of the  
747 experimental treatments. Treatments are indicated by (●) for those diets with  
748 incremental inclusion levels of DHA. Those diets with equivalent amounts of EPA (○)  
749 and ARA (Δ) are also indicated. Error bars show the pooled SEM.

750

751 Figure 3. Assessment of the behavioural responses of groups of fish within each treatment (n=3  
752 tanks, error bars show the SEM for each treatment) using either of two assessment  
753 methods. (a) After two rounds of feeding in each tank the number of pellets remaining  
754 to be fed as a percentage of the total amount being fed was recorded, and (b) Fish were  
755 assessed as being highly-active (2), moderately active (1) or slow and lethargic (0) in  
756 terms of their response to being fed. Treatments are indicated by (●) for those diets  
757 with incremental inclusion levels of DHA. Those diets with equivalent amounts of  
758 EPA (○) and ARA (Δ) are also indicated.

759

760 **Tables and Figures**

761

762 Table 1. Nutrient compositions of major dietary ingredients (all values are g/kg DM unless  
763 otherwise indicated).

764

Ingredient	SPI	WF	WG	DF	FO	DHA	ARA	OO	BF
Dry matter (g/kg)	93.7	87.7	93.1	94.8	99.7	99.9	99.6	99.9	99.9
Protein	94.6	12.6	82.2	71.8	0.4	0.6	0.8	0.9	0.6
Fat	1.1	1.1	2.9	2.0	94.0	96.4	92.9	97.3	94.6
Carbohydrate	1.0	85.7	14.2	8.4	5.6	3.0	6.3	1.8	4.8
Ash	3.3	0.6	0.7	17.8	0.0	0.0	0.0	0.0	0.0
Gross Energy (kJ/g)	22.6	16.0	21.7	18.7	39.1	39.1	38.4	39.3	37.5
<i>All fatty acids are %TFA</i>									
14:0	0.6	0.0	0.0	6.7	8.3	9.5	0.9	0.0	11.8
16:0	17.3	19.8	19.6	22.7	18.7	25.5	11.7	11.3	27.0
18:0	4.7	1.9	1.5	5.3	3.4	0.9	7.7	3.2	12.1
Total SFA	24.6	21.7	21.1	38.2	34.5	37.8	33.5	15.2	63.3
16:1n-7	0.8	1.0	0.0	7.1	10.2	1.9	0.3	0.8	1.0
18:1n-9	24.4	14.0	13.5	14.3	12.5	2.0	7.1	0.0	0.0
18:1n-7	1.9	1.2	1.0	0.0	0.0	0.0	0.0	73.0	31.4
Total MUFA	28.0	16.1	15.5	21.3	24.2	4.2	8.1	76.1	33.6
18:2n-6	41.7	56.0	59.7	1.8	1.3	0.5	0.0	8.2	3.1
18:3n-3	4.6	3.7	2.9	0.0	0.7	0.1	0.1	0.5	0.0
Total C18 PUFA	46.2	59.6	62.6	3.6	5.3	1.5	3.1	8.6	3.1
20:4n-6	0.0	0.0	0.0	1.5	1.1	0.9	49.7	0.0	0.0
20:5n-3	0.0	1.3	0.8	13.2	16.9	1.9	0.2	0.0	0.0
22:5n-6	0.0	0.0	0.0	0.0	0.0	1.7	0.0	0.0	0.0
22:6n-3	0.0	1.3	0.0	21.2	14.5	50.8	0.0	0.0	0.0
Total LC-PUFA	1.3	2.5	0.8	35.9	33.7	56.3	55.3	0.0	0.0
Total n-3	4.6	6.2	3.7	36.2	35.1	51.8	0.7	0.5	0.0
Total n-6	41.7	56.0	59.7	3.3	3.9	6.1	57.6	8.2	3.1
n-3 : n-6	0.1	0.1	0.1	10.9	9.0	8.5	0.0	0.1	0.0

765 SPI : Soy protein isolate, WF : Wheat flour, WG : Wheat gluten, DF : Defatted fishmeal, FO : Fish  
766 oil, DHA : DHASCO, ARA : ARASCO, OO : Olive oil, BF : Butterfat.

767



768  
769

Table 2. Formulations of the experiment diets (all values are g/kg).

	D1	D5	D10	D15	D20	D10A	D10E	D5E
Defatted Fish meal <sup>a</sup>	300.0	300.0	300.0	300.0	300.0	300.0	300.0	300.0
Pregelised starch <sup>b</sup>	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0
Wheat gluten <sup>b</sup>	60.0	60.0	60.0	60.0	60.0	60.0	60.0	60.0
Wheat flour <sup>b</sup>	155.0	155.0	155.0	155.0	155.0	155.0	155.0	155.0
Soy Protein Isolate <sup>c</sup>	221.0	221.0	221.0	221.0	221.0	221.0	221.0	221.0
Fish oil <sup>a</sup>	0.0	0.0	0.0	0.0	0.0	0.0	75.0	30.0
Olive oil <sup>d</sup>	92.5	88.3	82.0	77.8	71.5	68.3	55.0	77.5
DHASCO <sup>e</sup>	0.0	8.4	21.0	29.4	42.0	21.0	0.0	0.0
ARASCO <sup>e</sup>	0.0	0.0	0.0	0.0	0.0	27.5	0.0	0.0
Butter fat <sup>f</sup>	92.5	88.3	82.0	77.8	71.5	68.3	55.0	77.5
L-Histidine <sup>g</sup>	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
L-Lysine <sup>g</sup>	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
DL-Methionine <sup>g</sup>	4.0	4.0	4.0	4.0	4.0	4.0	4.0	4.0
L-Threonine <sup>g</sup>	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0
Yttrium oxide <sup>h</sup>	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0
CaPO <sub>4</sub> <sup>g</sup>	5.0	5.0	5.0	5.0	5.0	5.0	5.0	5.0
Vitamin/minerals <sup>i*</sup>	5.0	5.0	5.0	5.0	5.0	5.0	5.0	5.0

770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781

<sup>a</sup> Fish meal (prior to being defatted): Chilean anchovy meal and oil, Skretting Australia, Cambridge, TAS, Australia. <sup>b</sup> Wheat gluten, wheat flour and pregelatinised starch: Manildra, Auburn, NSW, Australia. <sup>c</sup> Soy protein isolate: ADM, Decatur, IL, USA. <sup>d</sup> Refined olive oil: Conga Foods, Coburg North, VIC, Australia. <sup>e</sup> DHASCO and ARASCO oils: HuaTai BioPharm Inc, Deyang, Sichuan, China. <sup>f</sup> Butterfat: Woolworths Dairies, Bella Vista, NSW, Australia. <sup>g</sup> Amino acids and monocalcium phosphate: BEC Feed Solutions, Carole Park, QLD, Australia. <sup>h</sup> Yttrium oxide: Stanford Materials, Aliso Viejo, California, United States. <sup>i\*</sup> Vitamin and mineral premix includes (IU kg<sup>-1</sup> or g/kg of premix): Vitamin A, 2.5MIU; Vitamin D3, 0.25 MIU; Vitamin E, 16.7 g; Vitamin K<sub>3</sub>, 1.7 g; Vitamin B1, 2.5 g; Vitamin B2, 4.2 g; Vitamin B3, 25 g; Vitamin B5, 8.3; Vitamin B6, 2.0 g; Vitamin B9, 0.8; Vitamin B12, 0.005 g; Biotin, 0.17 g; Vitamin C, 75 g; Choline, 166.7 g; Inositol, 58.3 g; Ethoxyquin, 20.8 g; Copper, 2.5 g; Ferrous iron, 10.0 g; Magnesium, 16.6 g; Manganese, 15.0 g; Zinc, 25.0 g.

782 Table 3. Nutrient composition of experimental diets

	D1	D5	D10	D15	D20	D10A	D10E	D5E
Dry matter (g/kg)	958	967	952	961	943	921	946	944
Protein (g/kg DM)	525	526	511	513	521	519	517	518
Fat (g/kg DM)	181	176	204	205	204	178	186	182
Carbohydrate (g/kg DM)	186	239	230	253	206	214	194	213
Ash (g/kg DM)	82	72	68	69	71	86	82	74
Gross Energy (kJ/g)	22.3	22.4	23.1	22.7	22.1	22.7	22.5	23.0
Protein:Energy (g/MJ)	23.5	23.5	22.1	22.6	23.6	22.9	23.0	22.5
<i>All fatty acid data are %TFA</i>								
14:0	6.2	6.0	6.7	6.8	7.4	5.8	7.3	6.8
16:0	21.5	20.6	21.5	22.9	23.7	20.7	21.9	22.5
18:0	8.4	7.7	7.3	7.7	7.2	7.4	6.9	7.8
Total SFA	36.7	34.4	35.9	37.3	38.7	34.9	36.6	37.4
16:1n-7	1.4	1.3	1.8	1.9	2.1	1.4	5.1	3.2
18:1n-9	49.7	48.2	44.3	42.5	39.2	38.8	35.5	43.5
18:1n-7	4.0	3.9	3.7	3.7	3.7	3.1	3.8	4.0
Total MUFA	56.0	54.1	51.1	49.1	46.0	44.1	45.8	51.7
18:2n-6	5.8	6.7	5.9	5.3	4.9	6.5	5.6	6.1
18:3n-3	0.5	0.8	0.6	0.5	0.5	0.6	0.7	0.6
Total C18 PUFA	6.4	8.0	7.1	5.8	5.6	7.4	7.6	7.1
20:4n-6	0.1	0.1	0.1	0.1	0.1	5.1	0.4	0.1
20:5n-3	0.4	0.6	0.5	0.4	0.4	0.6	4.8	2.0
22:5n-6	0.0	0.6	1.3	1.5	1.6	1.3	0.0	0.0
22:5n-3	0.0	0.1	0.2	0.0	0.0	1.9	0.6	0.0
22:6n-3	0.5	2.0	3.6	5.7	7.6	4.1	3.9	1.7
Total LC-PUFA	1.0	3.4	5.8	7.8	9.8	13.5	10.0	3.8
Total n-3	1.4	3.8	5.3	6.6	8.5	7.1	11.3	4.7
Total n-6	5.9	7.7	7.7	6.9	6.8	13.8	6.3	6.2
n-3 : n-6	0.24	0.49	0.69	0.96	1.25	0.52	1.78	0.76

783 %TFA = percentage of total fatty acids.

Tables 4. Growth, feed utilisation and survival over the 62-day experimental period.

a	D1	D5	D10	D15	D20	R <sup>2</sup>	F-value	P-value
Initial weight (g/fish)	110.8	112.5	110.7	113.7	109.2	0.022	0.070	0.808
Final weight (g/fish)	226.8	226.7	233.1	232.1	231.4	0.564	3.880	0.143
Weight gain (g/fish)	116.0	114.2	122.5	118.5	122.1	0.401	2.010	0.251
Gain rate d0-d62 (g/d)	1.87	1.84	1.98	1.91	1.97	0.401	2.010	0.251
Gain rate d42-d62 (g/d)	2.30	2.66	2.80	2.70	2.90	0.715	7.532	0.071
Feed intake (g/fish)	106.3	105.9	108.5	105.3	107.3	0.025	0.078	0.797
Feed Conversion (feed : gain)	0.95	0.96	0.90	0.90	0.90	0.534	3.440	0.161
Survival (%)	83%	85%	90%	88%	90%	0.744	8.709	0.060

b	D1	D10	D20	D10A	D10E	D5E	Pooled SEM
Initial weight (g/fish)	110.8	110.7	109.2	111.8	111.0	108.0	0.53
Final weight (g/fish)	226.8 <sup>a</sup>	233.1 <sup>ab</sup>	231.4 <sup>ab</sup>	231.9 <sup>ab</sup>	238.9 <sup>b</sup>	229.6 <sup>ab</sup>	1.49
Weight gain (g/fish)	116.0 <sup>a</sup>	122.5 <sup>ab</sup>	122.1 <sup>ab</sup>	120.1 <sup>ab</sup>	127.9 <sup>b</sup>	121.6 <sup>ab</sup>	1.39
Gain rate d0-d62 (g/d)	1.87 <sup>a</sup>	1.98 <sup>ab</sup>	1.97 <sup>ab</sup>	1.94 <sup>ab</sup>	2.06 <sup>b</sup>	1.96 <sup>ab</sup>	0.02
Gain rate d42-d62 (g/d)	2.30 <sup>a</sup>	2.80 <sup>b</sup>	2.90 <sup>b</sup>	2.99 <sup>b</sup>	2.92 <sup>b</sup>	2.75 <sup>ab</sup>	0.04
Feed intake (g/fish)	106.3	108.5	107.3	105.0	107.4	106.1	0.43
Feed Conversion (feed : gain)	0.95 <sup>b</sup>	0.90 <sup>ab</sup>	0.90 <sup>ab</sup>	0.91 <sup>ab</sup>	0.86 <sup>a</sup>	0.87 <sup>a</sup>	0.01

Table 5. Whole body proximate (g/kg live basis) and fatty acid (% of total) com

	Initial	D1	D5	D10	D15	D20	D10A	D10E
Dry matter	268	279	277	279	277	272	271	277
Protein	176	184	185	185	189	186	190	185
Fat	48 <sup>a</sup>	67 <sup>b</sup>	68 <sup>b</sup>	63 <sup>ab</sup>	65 <sup>ab</sup>	53 <sup>a</sup>	61 <sup>ab</sup>	64 <sup>ab</sup>
Ash	19	28	21	26	24	24	24	25
14:0	6.8 <sup>b</sup>	5.3 <sup>a</sup>	5.4 <sup>a</sup>	5.2 <sup>a</sup>	5.6 <sup>ab</sup>	5.6 <sup>ab</sup>	5.5 <sup>ab</sup>	5.9 <sup>ab</sup>
16:0	19.6 <sup>b</sup>	18.3 <sup>a</sup>	18.6 <sup>ab</sup>	17.4 <sup>a</sup>	19.4 <sup>b</sup>	19.5 <sup>b</sup>	19.0 <sup>ab</sup>	19.3 <sup>b</sup>
18:0	4.6 <sup>a</sup>	5.8 <sup>b</sup>	5.8 <sup>b</sup>	5.3 <sup>a</sup>	5.6 <sup>ab</sup>	5.4 <sup>a</sup>	5.5 <sup>ab</sup>	5.5 <sup>ab</sup>
Total SFA	33.0 <sup>b</sup>	30.5 <sup>a</sup>	30.7 <sup>a</sup>	29.1 <sup>a</sup>	31.6 <sup>ab</sup>	31.4 <sup>ab</sup>	31.0 <sup>ab</sup>	31.8 <sup>ab</sup>
16:1n-7	9.0 <sup>c</sup>	4.6 <sup>a</sup>	4.5 <sup>a</sup>	4.4 <sup>a</sup>	4.7 <sup>ab</sup>	4.7 <sup>ab</sup>	4.5 <sup>a</sup>	6.1 <sup>b</sup>
18:1n-9	18.5 <sup>a</sup>	38.4 <sup>c</sup>	39.3 <sup>c</sup>	36.9 <sup>bc</sup>	35.1 <sup>bc</sup>	33.1 <sup>bc</sup>	34.3 <sup>bc</sup>	31.8 <sup>b</sup>
18:1n-7	4.1	3.7	3.8	3.7	3.8	3.7	3.5	4.2
Total MUFA	34.6 <sup>a</sup>	50.1 <sup>c</sup>	51.0 <sup>c</sup>	48.4 <sup>bc</sup>	46.7 <sup>bc</sup>	44.2 <sup>b</sup>	44.7 <sup>b</sup>	45.0 <sup>bc</sup>
18:2n-6	6.1	6.1	6.2	6.5	6.3	6.4	6.8	6.3
18:3n-3	1.3 <sup>b</sup>	0.7 <sup>a</sup>	0.7 <sup>a</sup>	0.8 <sup>a</sup>	0.8 <sup>a</sup>	0.8 <sup>a</sup>	0.8 <sup>a</sup>	0.9 <sup>ab</sup>
Total C18 PUFA	9.1 <sup>b</sup>	7.6 <sup>a</sup>	7.6 <sup>a</sup>	8.2 <sup>ab</sup>	7.6 <sup>a</sup>	7.9 <sup>a</sup>	8.4 <sup>ab</sup>	8.0 <sup>a</sup>
20:4n-6	0.8 <sup>a</sup>	0.6 <sup>a</sup>	0.5 <sup>a</sup>	0.6 <sup>a</sup>	0.5 <sup>a</sup>	0.7 <sup>a</sup>	3.1 <sup>b</sup>	0.5 <sup>a</sup>
20:5n-3	8.0 <sup>c</sup>	3.0 <sup>ab</sup>	2.5 <sup>a</sup>	2.9 <sup>a</sup>	3.1 <sup>ab</sup>	3.1 <sup>ab</sup>	2.9 <sup>a</sup>	4.0 <sup>b</sup>
22:5n-6	0.3 <sup>a</sup>	0.2 <sup>a</sup>	0.4 <sup>ab</sup>	0.9 <sup>b</sup>	1.0 <sup>b</sup>	1.6 <sup>c</sup>	1.0 <sup>b</sup>	0.2 <sup>a</sup>
22:5n-3	2.6 <sup>b</sup>	1.1 <sup>a</sup>	0.9 <sup>a</sup>	1.2 <sup>a</sup>	1.1 <sup>a</sup>	1.1 <sup>a</sup>	1.0 <sup>a</sup>	1.5 <sup>ab</sup>
22:6n-3	10.3 <sup>b</sup>	5.4 <sup>a</sup>	5.1 <sup>a</sup>	7.3 <sup>ab</sup>	7.2 <sup>ab</sup>	9.0 <sup>b</sup>	6.5 <sup>a</sup>	7.6 <sup>ab</sup>
Total LC-PUFA	23.3 <sup>c</sup>	11.8 <sup>a</sup>	10.7 <sup>a</sup>	14.3 <sup>a</sup>	14.2 <sup>a</sup>	16.5 <sup>b</sup>	15.9 <sup>ab</sup>	15.2 <sup>ab</sup>
Total n-3	24.5 <sup>b</sup>	11.1 <sup>a</sup>	10.0 <sup>a</sup>	13.3 <sup>a</sup>	12.9 <sup>a</sup>	15.1 <sup>a</sup>	12.1 <sup>a</sup>	15.2 <sup>a</sup>
Total n-6	7.9 <sup>a</sup>	8.3 <sup>a</sup>	8.3 <sup>a</sup>	9.3 <sup>ab</sup>	8.9 <sup>a</sup>	9.4 <sup>ab</sup>	12.2 <sup>b</sup>	8.1 <sup>a</sup>
n-3 : n-6	3.09 <sup>c</sup>	1.35 <sup>a</sup>	1.21 <sup>a</sup>	1.44 <sup>ab</sup>	1.44 <sup>ab</sup>	1.62 <sup>b</sup>	0.99 <sup>a</sup>	1.88 <sup>b</sup>

Different superscripts indicate significant differences between means among treatments (P<0.05). Lac implies that there were no significant differences.

Table 6. Plasma biochemistry and blood haematology parameters

	Units	D1	D5	D10	D15	D20	D10A	D10E	D5E	Pooled SEM
Alanine Aminotransferase	IU L <sup>-1</sup>	6.0 <sup>a</sup>	5.7 <sup>a</sup>	5.7 <sup>a</sup>	5.3 <sup>a</sup>	9.3 <sup>a</sup>	12.7 <sup>b</sup>	6.0 <sup>a</sup>	6.3 <sup>a</sup>	0.7
Glutamate Dehydrogenase	IU L <sup>-1</sup>	28.7 <sup>ab</sup>	28.3 <sup>ab</sup>	23.7 <sup>a</sup>	33.0 <sup>ab</sup>	38.0 <sup>b</sup>	35.7 <sup>ab</sup>	27.0 <sup>ab</sup>	31.0 <sup>ab</sup>	1.9
Asparagine Aminotransferase	IU L <sup>-1</sup>	234 <sup>ab</sup>	193 <sup>ab</sup>	188 <sup>a</sup>	202 <sup>ba</sup>	205 <sup>ab</sup>	246 <sup>b</sup>	194 <sup>ab</sup>	213 <sup>ab</sup>	7.6
Creatine Kinase	IU L <sup>-1</sup>	25973	17717	23790	18287	21653	25817	22777	24880	1749
Creatinine	µmol L <sup>-1</sup>	29.7 <sup>ab</sup>	27.3 <sup>a</sup>	28.0 <sup>a</sup>	26.3 <sup>a</sup>	25.7 <sup>a</sup>	31.3 <sup>b</sup>	33.0 <sup>b</sup>	29.3 <sup>ab</sup>	0.8
Total Protein	g L <sup>-1</sup>	38.0 <sup>a</sup>	40.3 <sup>a</sup>	39.3 <sup>a</sup>	40.0 <sup>a</sup>	39.7 <sup>a</sup>	40.0 <sup>a</sup>	44.7 <sup>b</sup>	42.3 <sup>ab</sup>	0.6
Cholesterol	mmol L <sup>-1</sup>	6.8 <sup>a</sup>	7.6 <sup>ab</sup>	7.7 <sup>ab</sup>	7.1 <sup>ab</sup>	6.9 <sup>a</sup>	6.2 <sup>a</sup>	7.5 <sup>ab</sup>	8.2 <sup>b</sup>	0.2
Calcium	mmol L <sup>-1</sup>	2.93 <sup>ab</sup>	2.93 <sup>ab</sup>	2.90 <sup>ab</sup>	2.90 <sup>ab</sup>	2.83 <sup>a</sup>	2.93 <sup>ab</sup>	3.00 <sup>b</sup>	2.97 <sup>b</sup>	0.02
Potassium	mmol L <sup>-1</sup>	4.3	3.9	3.8	4.4	4.5	3.6	3.8	4.5	0.2
Sodium	mmol L <sup>-1</sup>	168 <sup>b</sup>	168 <sup>b</sup>	164 <sup>ab</sup>	160 <sup>a</sup>	166 <sup>ab</sup>	164 <sup>ab</sup>	166 <sup>ab</sup>	164 <sup>ab</sup>	1.1
Chloride	mmol L <sup>-1</sup>	133	133	131	129	133	130	130	131	0.8
Red Blood Cell Count	x10 <sup>12</sup> L <sup>-1</sup>	1.10 <sup>ab</sup>	1.20 <sup>b</sup>	1.10 <sup>ab</sup>	1.15 <sup>b</sup>	1.13 <sup>b</sup>	1.00 <sup>a</sup>	1.20 <sup>b</sup>	1.15 <sup>b</sup>	0.02
White Blood Cell Count	x10 <sup>9</sup> L <sup>-1</sup>	32.1	33.4	19.3	28.1	31.3	28.3	23.6	18.2	1.9
Haemoglobin	g L <sup>-1</sup>	126.0 <sup>ab</sup>	132.0 <sup>b</sup>	123.0 <sup>ab</sup>	136.5 <sup>b</sup>	126.7 <sup>ab</sup>	130.0 <sup>ab</sup>	126.7 <sup>ab</sup>	121.0 <sup>a</sup>	1.3
Packed Cell Volume	mL mL <sup>-1</sup>	0.54	0.57	0.53	0.60	0.54	0.57	0.54	0.53	0.01

Different superscripts indicate significant differences between means among treatments (P<0.05). Lack of a superscript implies that there were no significant differences.

Table 7. Clinical physical health assessment at the end of the 62-day experimental period. Other than gill score, data are percent (%) of total population presenting each symptom.

	D1	D5	D10	D15	D20	D10A	D10E	D5E	Pooled SEM
Pin head	0 <sup>a</sup>	2 <sup>ab</sup>	2 <sup>ab</sup>	4 <sup>b</sup>	0 <sup>a</sup>	4 <sup>b</sup>	5 <sup>b</sup>	0 <sup>a</sup>	0.8
Pectoral fin erosion	2 <sup>a</sup>	12 <sup>b</sup>	6 <sup>ab</sup>	2 <sup>a</sup>	0 <sup>a</sup>	0 <sup>a</sup>	13 <sup>b</sup>	4 <sup>a</sup>	1.5
Caudal fin erosion	7 <sup>b</sup>	2 <sup>a</sup>	7 <sup>b</sup>	0 <sup>a</sup>	2 <sup>a</sup>	0 <sup>a</sup>	2 <sup>a</sup>	7 <sup>b</sup>	1.1
Scale damage	2 <sup>a</sup>	6 <sup>ab</sup>	12 <sup>bc</sup>	0 <sup>a</sup>	4 <sup>a</sup>	19 <sup>c</sup>	2 <sup>a</sup>	0 <sup>a</sup>	2.3
Eye damage	2 <sup>ab</sup>	0 <sup>a</sup>	2 <sup>ab</sup>	4 <sup>b</sup>	0 <sup>a</sup>	2 <sup>ab</sup>	0 <sup>a</sup>	2 <sup>ab</sup>	0.6
AGD gill score	1.3 <sup>ab</sup>	1.6 <sup>ab</sup>	1.1 <sup>a</sup>	1.7 <sup>b</sup>	1.4 <sup>ab</sup>	1.5 <sup>ab</sup>	1.5 <sup>ab</sup>	1.4 <sup>ab</sup>	0.064

AGD : Amoebic Gill Disease. Score based on that reported in Taylor et al., 2009. All other data are reported as percentage of fish showing the particular clinical sign. Different superscripts indicate significant differences between means among treatments ( $P < 0.05$ ). Lack of a superscript implies that there were no significant differences.

Relative Deposition Efficiency (%)

b






Figure 1

IL10A Deposition Efficiency (%)

ab






Figure 2



DHA Inclusion Level (g/kg)



DHA Inclusion Level (g/kg)




Figure 3.